Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simonetta Buglioni

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Biomedicines|September 30, 2020
Vav1 Down-Modulates Akt2 Expression in Cells from Pancreatic Ductal Adenocarcinoma: Nuclear Vav1 as a Potential Regulator of Akt Related Malignancy in Pancreatic CancerSilvia Grassilli, Federica Brugnoli, Rossano Lattanzio, et al.
Medicine|April 18, 2015
HER2 status determination: analyzing the problems to find the solutionsIrene Terrenato, Ilaria Pennacchia, Simonetta Buglioni, et al.
JTO Clinical and Research Reports|December 9, 2025
DESTINY of Immunotherapy in Patients With <i>HER2</i> Mutant Lung Cancer: Case ReportLorenza Landi, Francesca Fusco, Enrico Melis, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 7, 2018
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrationsMatteo Allegretti, Alessandra Fabi, Simonetta Buglioni, et al.
The Journal of Pathology|September 5, 2002
Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activityNadia Zaffaroni, Chiara Della Porta, Raffaella Villa, et al.
Cancer Genetics and Cytogenetics|March 14, 2002
Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancerAnna M Cianciulli, Claudio Botti, Angela M Coletta, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast CancerFrancesca Di Modugno, Simonetta Buglioni, Marcella Mottolese, et al.
Oncology Reports|March 2, 2021
HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancerAlessandra Verdina, Micol Di Segni, Carla Azzurra Amoreo, et al.
JTO Clinical and Research Reports|August 3, 2023
Pretreated <i>EGFR</i><sup></sup>/<i>BRAF</i><sup></sup> Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case ReportCorrado Orciuolo, Federico Cappuzzo, Lorenza Landi, et al.
The American Journal of Surgical Pathology|January 27, 2007
Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profileMarcella Mottolese, Giulia Orlandi, Isabella Sperduti, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Biomedicines|September 30, 2020
Vav1 Down-Modulates Akt2 Expression in Cells from Pancreatic Ductal Adenocarcinoma: Nuclear Vav1 as a Potential Regulator of Akt Related Malignancy in Pancreatic CancerSilvia Grassilli, Federica Brugnoli, Rossano Lattanzio, et al.
Medicine|April 18, 2015
HER2 status determination: analyzing the problems to find the solutionsIrene Terrenato, Ilaria Pennacchia, Simonetta Buglioni, et al.
JTO Clinical and Research Reports|December 9, 2025
DESTINY of Immunotherapy in Patients With <i>HER2</i> Mutant Lung Cancer: Case ReportLorenza Landi, Francesca Fusco, Enrico Melis, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 7, 2018
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrationsMatteo Allegretti, Alessandra Fabi, Simonetta Buglioni, et al.
The Journal of Pathology|September 5, 2002
Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activityNadia Zaffaroni, Chiara Della Porta, Raffaella Villa, et al.
Cancer Genetics and Cytogenetics|March 14, 2002
Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancerAnna M Cianciulli, Claudio Botti, Angela M Coletta, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast CancerFrancesca Di Modugno, Simonetta Buglioni, Marcella Mottolese, et al.
Oncology Reports|March 2, 2021
HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancerAlessandra Verdina, Micol Di Segni, Carla Azzurra Amoreo, et al.
JTO Clinical and Research Reports|August 3, 2023
Pretreated <i>EGFR</i><sup></sup>/<i>BRAF</i><sup></sup> Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case ReportCorrado Orciuolo, Federico Cappuzzo, Lorenza Landi, et al.
The American Journal of Surgical Pathology|January 27, 2007
Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profileMarcella Mottolese, Giulia Orlandi, Isabella Sperduti, et al.
Pageof 9